Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 9/2014

01-09-2014 | Urologic Oncology

Independent Predictors for Bladder Outcomes after Treatment of Intravesical Recurrence following Radical Nephroureterectomy in Patients with Primary Upper Tract Urothelial Carcinoma

Authors: Nobuyuki Tanaka, MD, Eiji Kikuchi, MD, PhD, Kent Kanao, MD, PhD, Kazuhiro Matsumoto, MD, Suguru Shirotake, MD, PhD, Hiroaki Kobayashi, MD, Yasumasa Miyazaki, MD, Hiroki Ide, MD, Jun Obata, MD, Katsura Hoshino, MD, Nozomi Hayakawa, MD, Masayuki Hagiwara, MD, Takeo Kosaka, MD, PhD, Masafumi Oyama, MD, PhD, Akira Miyajima, MD, PhD, Tetsuo Momma, MD, PhD, Ken Nakagawa, MD, PhD, Masahiro Jinzaki, MD, PhD, Shintaro Hasegawa, MD, PhD, Yosuke Nakajima, MD, PhD, Mototsugu Oya, MD, PhD

Published in: Annals of Surgical Oncology | Issue 9/2014

Login to get access

Abstract

Background

Few studies have described the clinical courses and outcomes in the bladder after treatment of intravesical recurrence after radical nephroureterectomy (RNU) in patients with primary upper tract urothelial carcinoma (UTUC). We investigated the indicators for predicting subsequent bladder outcomes after treatment of intravesical recurrence after RNU.

Methods

A total of 241 patients with primary UTUC (pTa-4N0M0) who experienced intravesical recurrence after RNU were included. Of these patients, 101 (41.9 %) underwent Bacillus Calmette-Guérin treatments, whereas 49 (20.3 %) underwent intravesical chemotherapy. The median follow-up period after initial transurethral resection of the bladder tumor was 33 months. Relationships with bladder outcomes were analyzed by using multivariable analysis.

Results

Ninety-six patients experienced intravesical recurrence, and bladder progression was observed in 13. Cumulative incidence rates of intravesical recurrence at 1 and 5 years after treatment of the first intravesical recurrence were 31.0 and 48.4 %, whereas those of bladder progression at 1 and 5 years thereafter were 2.4 and 8.0 %. Multivariate analysis showed that the number of recurrent tumors and pT1 tumors at the time of the first intravesical relapse were independent risk factors for subsequent intravesical recurrence. With respect to bladder progression, multivariate analysis showed that pT1 tumors, the appearance of concomitant carcinoma-in situ at the time of the first intravesical relapse, and the absence of the Bacillus Calmette-Guérin treatment were independent risk factors.

Conclusions

This retrospective study presents a detailed picture of further bladder outcomes after intravesical recurrence after RNU in primary UTUC patients. The results may assist physicians to develop a more rational protocol in bladder surveillance.
Literature
1.
Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212–36.PubMedCrossRef
2.
Roupret M, Babjuk M, Comperat E, et al. European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol. 2013;63:1059–71.PubMedCrossRef
3.
Xylinas E, Colin P, Audenet F, et al. Intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinomas: predictors and impact on subsequent oncological outcomes from a national multicenter study. World J Urol. 2013;31:61–8.PubMedCrossRef
4.
O’Brien T, Ray E, Singh R, et al. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). Eur Urol. 2011;60:703–10.PubMedCrossRef
5.
Azemar MD, Comperat E, Richard F, et al. Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: frequency, risk factors, and surveillance. Urol Oncol. 2011;29:130–6.PubMedCrossRef
6.
Novara G, De Marco V, Dalpiaz O, et al. Independent predictors of metachronous bladder transitional cell carcinoma (TCC) after nephroureterectomy for TCC of the upper urinary tract. BJU Int. 2008;101:1368–74.PubMedCrossRef
7.
Abe T, Shinohara N, Harabayashi T, et al. Pathological characteristics and clinical course of bladder tumour developing after nephroureterectomy. BJU Int. 2010;105:1102–6.PubMedCrossRef
8.
Tanaka N, Kikuchi E, Kanao K, et al. The predictive value of positive urine cytology for outcomes following radical nephroureterectomy in patients with primary upper tract urothelial carcinoma: a multi-institutional study. Urol Oncol. 2014;32:48.e19–26.PubMed
9.
Kim KH, You D, Jeong IG, et al. Muscle-invasive bladder cancer developing after nephroureterectomy for upper urinary tract urothelial carcinoma. Urol Oncol. 2013;31:1643–9.PubMedCrossRef
10.
Li CC, Chang TH, Wu WJ, et al. Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients. Eur Urol. 2008;54:1127–34.PubMedCrossRef
11.
Kobayashi Y, Saika T, Miyaji Y, et al. Preoperative positive urine cytology is a risk factor for subsequent development of bladder cancer after nephroureterectomy in patients with upper urinary tract urothelial carcinoma. World J Urol. 2012;30:271–5.PubMedCrossRef
12.
Takaoka E, Hinotsu S, Joraku A, et al. Pattern of intravesical recurrence after surgical treatment for urothelial cancer of the upper urinary tract: a single institutional retrospective long-term follow-up study. Int J Urol. 2010;17:623–8.PubMedCrossRef
13.
Ku JH, Choi WS, Kwak C, Kim HH. Bladder cancer after nephroureterectomy in patients with urothelial carcinoma of the upper urinary tract. Urol Oncol. 2011;29:383–7.PubMedCrossRef
14.
Kusuda Y, Miyake H, Terakawa T, et al. Gender as a significant predictor of intravesical recurrence in patients with urothelial carcinoma of the upper urinary tract following nephroureterectomy. Urol Oncol. 2013;31:899–903.PubMedCrossRef
15.
Hagiwara M, Kikuchi E, Tanaka N, et al. Impact of smoking status on bladder tumor recurrence after radical nephroureterectomy for upper tract urothelial carcinoma. J Urol. 2013;189:2062–8.PubMedCrossRef
16.
Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466–5. discussion 475–67.
17.
Babjuk M, Burger M, Zigeuner R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013;64:639–53.PubMedCrossRef
18.
Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361–87.PubMedCrossRef
19.
Fernandez-Gomez J, Solsona E, Unda M, et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: multivariate analysis of data from four randomized CUETO trials. Eur Urol. 2008;53:992–1001.PubMedCrossRef
20.
Thomas F, Noon AP, Rubin N, et al. Comparative outcomes of primary, recurrent, and progressive high-risk non-muscle-invasive bladder cancer. Eur Urol. 2013;63:145–54.PubMedCrossRef
21.
Tanaka N, Kikuchi E, Matsumoto K, et al. Frequency of tumor recurrence: a strong predictor of stage progression in initially diagnosed nonmuscle invasive bladder cancer. J Urol. 2011;185:450–5.PubMedCrossRef
Metadata
Title
Independent Predictors for Bladder Outcomes after Treatment of Intravesical Recurrence following Radical Nephroureterectomy in Patients with Primary Upper Tract Urothelial Carcinoma
Authors
Nobuyuki Tanaka, MD
Eiji Kikuchi, MD, PhD
Kent Kanao, MD, PhD
Kazuhiro Matsumoto, MD
Suguru Shirotake, MD, PhD
Hiroaki Kobayashi, MD
Yasumasa Miyazaki, MD
Hiroki Ide, MD
Jun Obata, MD
Katsura Hoshino, MD
Nozomi Hayakawa, MD
Masayuki Hagiwara, MD
Takeo Kosaka, MD, PhD
Masafumi Oyama, MD, PhD
Akira Miyajima, MD, PhD
Tetsuo Momma, MD, PhD
Ken Nakagawa, MD, PhD
Masahiro Jinzaki, MD, PhD
Shintaro Hasegawa, MD, PhD
Yosuke Nakajima, MD, PhD
Mototsugu Oya, MD, PhD
Publication date
01-09-2014
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 9/2014
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-3657-y

Other articles of this Issue 9/2014

Annals of Surgical Oncology 9/2014 Go to the issue

Endocrine Tumors

Does Completion Thyroidectomy Improve the Outcome of Patients with Minimally Invasive Follicular Carcinoma of the Thyroid?

Hepatobiliary Tumors

Comparison of Survival of Patients with BCLC Stage A Hepatocellular Carcinoma After Hepatic Resection or Transarterial Chemoembolization: A Propensity Score-Based Analysis

Pancreatic Tumors

Reply to ‘Letter to the Editor of Annals of Surgical Oncology Concerning “Robotic versus Open Pancreatectomy: A Systematic Review and Meta-Analysis”,’ by Petrucciani Niccolò, et al. (ASO-2013-09-1427)

Thoracic Oncology

Number of Negative Lymph Nodes is Associated with Survival in Thoracic Esophageal Squamous Cell Carcinoma Patients Undergoing Three-Field Lymphadenectomy

Breast Oncology

Local Recurrence Rates are Low in High-Risk Neoadjuvant Breast Cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657)

Pancreatic Tumors

Basing Treatment Strategy for Non-functional Pancreatic Neuroendocrine Tumors on Tumor Size